Welcome to our dedicated page for Crescent Biopharma news (Ticker: cbio), a resource for investors and traders seeking the latest updates and insights on Crescent Biopharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Crescent Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Crescent Biopharma's position in the market.
Crescent Biopharma (Nasdaq: CBIO) announced inducement equity awards approved March 26, 2026. The independent Compensation Committee granted options to purchase a total of 35,325 ordinary shares to three non-executive employees under the 2025 Inducement Plan.
The options have a 10-year term, an exercise price of $13.50 (Nasdaq close on March 26, 2026), and vest 25% after one year then monthly thereafter (1/48th per month), subject to continuous service and plan terms.
Crescent Biopharma (Nasdaq: CBIO) announced inducement option awards totaling 45,675 shares to two non-executive employees, approved March 5, 2026 under its 2025 Employment Inducement Incentive Award Plan. The options carry a 10-year term and an exercise price of $11.33 (Nasdaq close on March 5, 2026).
Vesting: 25% vests on the first anniversary of each employee’s start date, then 1/48th monthly thereafter, subject to continuous service and the plan and option agreement terms; grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Crescent Biopharma (Nasdaq: CBIO) reported Q4 and full‑year 2025 results and business updates on Feb 26, 2026, highlighting a strategic partnership with Kelun‑Biotech, IND clearance and patient dosing for CR‑001, a global ASCEND Phase 1/2 trial, and a completed $185 million private placement that supports operations into 2028.
Crescent Biopharma (Nasdaq: CBIO) will present at two investor conferences in March 2026: TD Cowen on March 2 at 3:50 p.m. ET in Boston and Leerink Partners on March 11 at 8:40 a.m. ET in Miami.
According to Crescent Biopharma, each presentation will be webcast live and replays will be available via the Investors section of the company's website for 90 days.
Crescent Biopharma (Nasdaq: CBIO) announced inducement option awards totaling 24,600 shares to two non-executive employees approved February 17, 2026. The options have a 10-year term and an exercise price of $9.33, the February 17, 2026 closing price.
Vesting: 1/4 after one year from each employee's start date, then 1/48 monthly thereafter, subject to continuous service and plan terms.
Crescent Biopharma (Nasdaq: CBIO) announced dosing of the first patient in the global ASCEND Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody, for advanced solid tumors on Feb 18, 2026.
ASCEND may enroll up to 290 patients across the US, Europe and Asia Pacific; the company expects proof-of-concept data in Q1 2027 and said ASCEND is the first of four portfolio trials planned to start in 2026.
Crescent Biopharma (Nasdaq: CBIO) management will present in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on Thursday, February 12, 2026 at 11:30 a.m. ET. A live webcast will be available in the Investors section and a replay will be accessible for 90 days.
Crescent Biopharma (Nasdaq: CBIO) announced inducement equity option awards approved January 29, 2026, granting an aggregate of 117,339 options to five non-executive employees under the 2025 Employment Inducement Incentive Award Plan.
Options have a 10-year term, exercise price of $10.15, and standard four-year vesting with monthly vesting thereafter.
Crescent Biopharma (Nasdaq: CBIO) announced IND clearances for two oncology candidates: CR-001 (PD-1 x VEGF bispecific) cleared by the U.S. FDA and CR-003 (ITGB6-targeted ADC/SKB105) approved by China NMPA CDE via partner Kelun-Biotech. Crescent plans a global Phase 1/2 ASCEND trial for CR-001 in first-line and previously treated solid tumor patients, targeting enrollment of up to 290 participants and on track to start in Q1 2026. Proof-of-concept data from ASCEND is anticipated in Q1 2027. Crescent expects four clinical trials across its portfolio to initiate in 2026. The strategic collaboration with Kelun-Biotech defines ex-China and Greater China commercialization rights for the two programs.
Crescent Biopharma (Nasdaq: CBIO) announced inducement option awards to three non-executive employees under its 2025 Employment Inducement Incentive Award Plan.
The Board approved an aggregate of 129,626 options on December 13, 2025, and the options were granted on December 15, 2025. Each option has a 10-year term and an exercise price of $13.21, equal to the Nasdaq closing price on December 15, 2025. Vesting is 25% after the first anniversary of each employee’s start date, then monthly at 1/48th thereafter, subject to continuous service and the Inducement Plan terms.